Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark.
Department of Bacteria, Parasites and Fungi, Statens Serum Institut, Copenhagen, Denmark.
Eur J Clin Microbiol Infect Dis. 2022 Dec;41(12):1473-1477. doi: 10.1007/s10096-022-04513-5. Epub 2022 Oct 25.
This study aimed to estimate the effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) against invasive pneumococcal disease (IPD) among individuals ≥ 65 years of age. We used Danish nationwide databases to obtain information on PPV23 vaccination, covariates, and IPD and linked data on an individual level using a unique personal identifier. A total of 948,263 individuals were included and followed between June 15, 2020, and September 18, 2021 (58.6% were vaccinated during follow-up). The adjusted vaccine effectiveness was 42% (95% confidence interval (CI): 9-63%) for all-serotype IPD and 58% (95% CI: 21-78%) for PPV23-serotype IPD, using no vaccination as the reference.
这项研究旨在评估 23 价肺炎球菌多糖疫苗（PPV23）对≥65 岁人群中侵袭性肺炎球菌病（IPD）的有效性。我们使用丹麦全国性数据库获取关于 PPV23 疫苗接种、协变量以及 IPD 的信息，并使用唯一的个人标识符在个体层面上对数据进行关联。共纳入 948263 名参与者，并于 2020 年 6 月 15 日至 2021 年 9 月 18 日期间进行随访（58.6%的参与者在随访期间接种了疫苗）。调整后的疫苗有效性为所有血清型 IPD 的 42%（95%置信区间（CI）：9-63%）和 PPV23 血清型 IPD 的 58%（95% CI：21-78%），以未接种疫苗作为参照。
